Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPID: Rifaximin for Prevention of C. difficile Relapse
NCT01670149Phase 4Completed
- Sponsor
- University of Nottingham
- Start
- Dec 2012
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Clostridioides difficile infection (CDI) comparing Rifaximin with Placebo (2 arms). Primary endpoint: Difference in % relapse between Rifaximin and placebo at 12 weeks. Started Dec 2012; status: completed.
02
Drugs
rifaximin
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT01670149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01670149.